Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Defamation Litigation Roundup: Jay-Z, Blake Lively, Drake No Photo Available

Theresa Schliep

In this month's review of ongoing defamation fights, Law360 looks back on an escalation in Jay-Z's case against personal injury lawyer... (more story)

Already Lean US Trustee Program Sees 58 Take Buyouts No Photo Available

Vince Sullivan

Dozens of employees of the United States Trustee Program have taken buyouts offered by the federal government, Law360 has learned, lea... (more story)

Avison Young's Miami Team Thrives In Full-Court Press No Photo Available

Nathan Hale

When a high-profile piece of property lands in the middle of a court case in Florida, there's a good chance the phone will soon be rin... (more story)